GSK CEO Declares US Market Top Priority Amid Trump’s Drug Pricing Pressure

The pharmaceutical landscape is undergoing a critical transformation as GSK (GlaxoSmithKline) places the United States market at the center of its growth strategy. With political and regulatory challenges intensifying, especially under the shadow of former President Donald Trump’s long-standing pressure on lowering drug pricing, GSK’s leadership has taken a clear stance. By prioritizing the U.S. market, the company signals both its determination to capture long-term opportunities and its readiness to navigate political headwinds.